Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American society of clinical oncology clinical practice guideline

Journal of Clinical Oncology

Volumn 35, Issue 8, 2017, Pages 893-911

  Armenian, Saro H ^a,b   Lacchetti, Christina ^b   Barac, Ana ^d   Carver, Joseph ^e   Constine, Louis S ^g   Denduluri, Neelima ^c   Dent, Susan ⁱ   Douglas, Pamela S ^j   Durand, Jean Bernard ^k   Ewer, Michael ^k   Fabian, Carol ^l   Hudson, Melissa ^m   Jessup, Mariell ^e   Jones, Lee W ^h   Ky, Bonnie ^f   Mayer, Erica L ^p   Moslehi, Javid ⁿ   Oeffinger, Kevin ^h   Ray, Katharine ^o   Ruddy, Kathryn ^q   Lenihan, Daniel ⁿ   more..

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^c Virginia Cancer Specialists PC   (United States)

^d WASHINGTON HOSPITAL CENTER   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^g UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁱ OTTAWA REGIONAL CANCER CENTRE   (Canada)

^j DUKE UNIVERSITY   (United States)

^k UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^l UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^m ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

ⁿ VANDERBILT UNIVERSITY   (United States)

^o Patient Representative   (United States)

^p DANA FARBER CANCER INSTITUTE   (United States)

^q MAYO CLINIC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; PHOSPHOTRANSFERASE INHIBITOR; TRASTUZUMAB;

CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVOR; CANCER THERAPY; CARDIOTOXICITY; COMORBIDITY; HEALTH DISPARITY; HEART DISEASE; HEART FUNCTION; HUMAN; INTERPERSONAL COMMUNICATION; MALIGNANT NEOPLASM; META ANALYSIS; MULTIPLE CHRONIC CONDITIONS; OBSERVATIONAL STUDY; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; ADULT; HEART; NEOPLASM; PATHOPHYSIOLOGY; SURVIVOR;

ADULT; HEART; HEART DISEASES; HUMANS; NEOPLASMS; SURVIVORS;

EID: 85015715684     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.70.5400     Document Type: Review

References (161)

1. American Society of Clinical Oncology: The state of cancer care in America, 2015: A report by the American Society of Clinical Oncology. J Oncol Pract 11: 79-113, 2015
2. Yancy CW, Jessup M, Bozkurt B, et al: 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 128: e240-e327, 2013
3. Lipshultz SE, Adams MJ, Colan SD, et al: Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: Pathophysiology, course, monitoring, management, prevention, and research directions-A scientific statement from the American Heart Association. Circulation 128: 1927-1995, 2013
4. Armenian SH, Hudson MM, Mulder RL, et al: Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: A report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol 16: e123-e136, 2015
5. Shea BJ, Grimshaw JM, Wells GA, et al: Development of AMSTAR: A measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol 7: 10, 2007
6. Wells GA, Shea B, O'Connell D, et al: The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp
7. Smith LA, Cornelius VR, Plummer CJ, et al: Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials. BMC Cancer 10: 337, 2010
8. van Dalen EC, Michiels EM, Caron HN, et al: Different anthracycline derivatives for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev 5: CD005006, 2010
9. Kalam K, Marwick TH: Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: A systematic review and meta-analysis. Eur J Cancer 49: 2900-2909, 2013
10. van Dalen EC, Caron HN, Dickinson HO, et al: Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 6: CD003917, 2011
11. Thavendiranathan P, Poulin F, Lim KD, et al: Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: A systematic review. J Am Coll Cardiol 63: 2751-2768, 2014
12. Thavendiranathan P, Wintersperger BJ, Flamm SD, et al: Cardiac MRI in the assessment of cardiac injury and toxicity from cancer chemotherapy: A systematic review. Circ Cardiovasc Imaging 6: 1080-1091, 2013
13. Polk A, Vaage-Nilsen M, Vistisen K, et al: Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: A systematic review of incidence, manifestations and predisposing factors. Cancer Treat Rev 39: 974-984, 2013
14. Viani GA, Afonso SL, Stefano EJ, et al: Adjuvant trastuzumab in the treatment of HER-2-positive early breast cancer: A meta-analysis of published randomized trials. BMC Cancer 7: 153, 2007
15. Baldini E, Prochilo T, Salvadori B, et al: Multicenter randomized phase III trial of epirubicin plus paclitaxel vs epirubicin followed by paclitaxel in metastatic breast cancer patients: Focus on cardiac safety. Br J Cancer 91: 45-49, 2004
16. Bonneterre J, RochéH, Kerbrat P, et al: Longterm cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group. J Clin Oncol 22: 3070-3079, 2004
17. Romond EH, Jeong J-H, Rastogi P, et al: Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 30: 3792-3799, 2012
18. Tan-Chiu E, Yothers G, Romond E, et al: Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23: 7811-7819, 2005
19. Chan S, Davidson N, Juozaityte E, et al: Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. Ann Oncol 15: 1527-1534, 2004
20. Kaya MG, Ozkan M, Gunebakmaz O, et al: Protective effects of nebivolol against anthracyclineinduced cardiomyopathy: A randomized control study. Int J Cardiol 167: 2306-2310, 2013
21. Zhang H, Shen WS, Gao CH, et al: Protective effects of salidroside on epirubicin-induced early left ventricular regional systolic dysfunction in patients with breast cancer. Drugs R D 12: 101-106, 2012
22. Swain SM, Ewer MS, Cortés J, et al: Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: A randomized, doubleblind, placebo-controlled phase III study. Oncologist 18: 257-264, 2013
23. Perez EA, Suman VJ, Davidson NE, et al: Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 26: 1231-1238, 2008
24. Procter M, Suter TM, de Azambuja E, et al: Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol 28: 3422-3428, 2010
25. Cadeddu C, Piras A, Mantovani G, et al: Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment. Am Heart J 160: 487.e1-487.e7, 2010
26. Advani PP, Ballman KV, Dockter TJ, et al: Long-term cardiac safety analysis of NCCTG N9831 (Alliance) adjuvant trastuzumab trial. J Clin Oncol 34: 581-587, 2016
27. Cardinale D, Colombo A, Bacchiani G, et al: Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 131: 1981-1988, 2015
28. Neilan TG, Coelho-Filho OR, Pena-Herrera D, et al: Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines. Am J Cardiol 110: 1679-1686, 2012
29. Di Lorenzo G, Autorino R, Bruni G, et al: Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: A multicenter analysis. Ann Oncol 20: 1535-1542, 2009
30. Farolfi A, Melegari E, Aquilina M, et al: Trastuzumab-induced cardiotoxicity in early breast cancer patients: A retrospective study of possible risk and protective factors. Heart 99: 634-639, 2013
31. Limat S, Demesmay K, Voillat L, et al: Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma. Ann Oncol 14: 277-281, 2003
32. Serrano C, Cortés J, DeMattos-Arruda L, et al: Trastuzumab-related cardiotoxicity in the elderly: A role for cardiovascular risk factors. Ann Oncol 23: 897-902, 2012
33. Tarantini L, Gori S, Faggiano P, et al: Adjuvant trastuzumab cardiotoxicity in patients over 60 years of age with early breast cancer: A multicenter cohort analysis. Ann Oncol 23: 3058-3063, 2012
34. Brockstein BE, Smiley C, Al-Sadir J, et al: Cardiac and pulmonary toxicity in patients undergoing high-dose chemotherapy for lymphoma and breast cancer: Prognostic factors. Bone Marrow Transplant 25: 885-894, 2000
35. Chavez-MacGregor M, Zhang N, Buchholz TA, et al: Trastuzumab-related cardiotoxicity among older patientswith breast cancer. J Clin Oncol 31: 4222-4228, 2013
36. Fumoleau P, RochéH, Kerbrat P, et al: Longterm cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results. Ann Oncol 17: 85-92, 2006
37. Ryberg M, Nielsen D, Cortese G, et al: New insight into epirubicin cardiac toxicity: Competing risks analysis of 1097 breast cancer patients. J Natl Cancer Inst 100: 1058-1067, 2008
38. Seidman A, Hudis C, Pierri MK, et al: Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20: 1215-1221, 2002
39. Hooning MJ, Botma A, Aleman BM, et al: Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst 99: 365-375, 2007
40. Fried G, Regev T, Moskovitz M: Trastuzumabrelated cardiac events in the treatment of early breast cancer. Breast Cancer Res Treat 142: 1-7, 2013
41. Lemieux J, Diorio C, CôtéMA, et al: Alcohol and HER2 polymorphisms as risk factor for cardiotoxicity in breast cancer treated with trastuzumab. Anticancer Res 33: 2569-2576, 2013
42. Maduro JH, den Dekker HA, Pras E, et al: Cardiovascular morbidity after radiotherapy or chemoradiation in patients with cervical cancer. Int J Radiat Oncol Biol Phys 78: 1337-1344, 2010
43. Hershman DL, McBride RB, Eisenberger A, et al: Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma. J Clin Oncol 26: 3159-3165, 2008
44. Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al: Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 109: 1878-1886, 2007
45. Armenian SH, Sun CL, Shannon T, et al: Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantation. Blood 118: 6023-6029, 2011
46. Avilés A, Neri N, Nambo JM, et al: Late cardiac toxicity secondary to treatment in Hodgkin's disease: A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapy. Leuk Lymphoma 46: 1023-1028, 2005
47. Chow EJ, Mueller BA, Baker KS, et al: Cardiovascular hospitalizations and mortality among recipients of hematopoietic stem cell transplantation. Ann Intern Med 155: 21-32, 2011
48. Harris EE, Correa C, Hwang WT, et al: Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment. J Clin Oncol 24: 4100-4106, 2006
49. Guarneri V, Lenihan DJ, Valero V, et al: Longterm cardiac tolerability of trastuzumab in metastatic breast cancer: The M.D. Anderson Cancer Center experience. J Clin Oncol 24: 4107-4115, 2006
50. Naumann D, Rusius V, Margiotta C, et al: Factors predicting trastuzumab-related cardiotoxicity in a real-world population of women with HER21 breast cancer. Anticancer Res 33: 1717-1720, 2013
51. Boerman LM, Berendsen AJ, van der Meer P, et al: Long-term follow-up for cardiovascular disease after chemotherapy and/or radiotherapy for breast cancer in an unselected population. Support Care Cancer 22: 1949-1958, 2014
52. Cao L, Hu WG, Kirova YM, et al: Potential impact of cardiac dose-volume on acute cardiac toxicity following concurrent trastuzumab and radiotherapy. Cancer Radiother 18: 119-124, 2014
53. Hequet O, Le QH, Moullet I, et al: Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol 22: 1864-1871, 2004
54. Doyle JJ, Neugut AI, Jacobson JS, et al: Chemotherapy and cardiotoxicity in older breast cancer patients: A population-based study. J Clin Oncol 23: 8597-8605, 2005
55. Pinder MC, Duan Z, Goodwin JS, et al: Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 25: 3808-3815, 2007
56. Hilbers FS, Boekel NB, van den Broek AJ, et al: Genetic variants in TGFb-1 and PAI-1 as possible risk factors for cardiovascular disease after radiotherapy for breast cancer. Radiother Oncol 102: 115-121, 2012
57. Ibrahim NK, Hortobagyi GN, Ewer M, et al: Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: The M.D. Anderson experience. Cancer Chemother Pharmacol 43: 471-478, 1999
58. Ganz PA, Hussey MA, Moinpour CM, et al: Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897. J Clin Oncol 26: 1223-1230, 2008
59. Tallaj JA, Franco V, Rayburn BK, et al: Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure. J Heart Lung Transplant 24: 2196-2201, 2005
60. Seicean S, Seicean A, Alan N, et al: Cardioprotective effect of b-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: Follow-up study of heart failure. Circ Heart Fail 6: 420-426, 2013
61. Du XL, Xia R, Burau K, et al: Cardiac risk associated with the receipt of anthracycline and trastuzumab in a large nationwide cohort of older women with breast cancer, 1998-2005.Med Oncol 28: S80-S90, 2011 (suppl 1)
62. Moser EC, Noordijk EM, van Leeuwen FE, et al: Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. Blood 107: 2912-2919, 2006
63. Dang C, Guo H, Najita J, et al: Cardiac outcomes of patients receiving adjuvant weekly paclitaxel and trastuzumab for node-negative, ERBB2-positive breast cancer. JAMA Oncol 2: 29-36, 2016
64. van Nimwegen FA, Schaapveld M, Janus CP, et al: Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med 175: 1007-1017, 2015
65. Goldhar HA, Yan AT, Ko DT, et al: The temporal risk of heart failure associated with adjuvant trastuzumab in breast cancer patients: A population study. J Natl Cancer Inst 108: djv301, 2015
66. Civelli M, Cardinale D, Martinoni A, et al: Early reduction in left ventricular contractile reserve detected by dobutamine stress echo predicts high-dose chemotherapy-induced cardiac toxicity. Int J Cardiol 111: 120-126, 2006
67. Bowles EJ, Wellman R, Feigelson HS, et al: Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: A retrospective cohort study. J Natl Cancer Inst 104: 1293-1305, 2012
68. Chen J, Long JB, Hurria A, et al: Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol 60: 2504-2512, 2012
69. Jones SE, Collea R, Paul D, et al: Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: A single-group, open-label, phase 2 study. Lancet Oncol 14: 1121-1128, 2013
70. Petersen PM, Aznar MC, Berthelsen AK, et al: Prospective phase II trial of image-guided radiotherapy in Hodgkin lymphoma: Benefit of deep inspiration breath-hold. Acta Oncol 54: 60-66, 2015
71. Paumier A, Ghalibafian M, Gilmore J, et al: Dosimetric benefits of intensity-modulated radiotherapy combined with the deep-inspiration breathhold technique in patients with mediastinal Hodgkin's lymphoma. Int J RadiatOncol Biol Phys 82: 1522-1527, 2012
72. Charpentier AM, Conrad T, Sykes J, et al: Active breathing control for patients receiving mediastinal radiation therapy for lymphoma: Impact on normal tissue dose. Pract Radiat Oncol 4: 174-180, 2014
73. Hoppe BS, Flampouri S, Su Z, et al: Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 84: 449-455, 2012
74. Hoppe BS, Flampouri S, Su Z, et al: Consolidative involved-node proton therapy for stage IA-IIIB mediastinal Hodgkin lymphoma: Preliminary dosimetric outcomes from a phase II study. Int J Radiat Oncol Biol Phys 83: 260-267, 2012
75. Koeck J, Abo-Madyan Y, Lohr F, et al: Radiotherapy for early mediastinal Hodgkin lymphoma according to the German Hodgkin Study Group (GHSG): The roles of intensity-modulated radiotherapy and involved-node radiotherapy. Int J Radiat Oncol Biol Phys 83: 268-276, 2012
76. Campbell BA, Hornby C, Cunninghame J, et al: Minimising critical organ irradiation in limited stage Hodgkin lymphoma: A dosimetric study of the benefit of involved node radiotherapy. Ann Oncol 23: 1259-1266, 2012
77. Ky B, Putt M, Sawaya H, et al: Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol 63: 809-816, 2014
78. Sawaya H, Sebag IA, Plana JC, et al: Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging 5: 596-603, 2012
79. Specchia G, Buquicchio C, Pansini N, et al: Monitoring of cardiac function on the basis of serum troponin I levels in patients with acute leukemia treated with anthracyclines. J Lab Clin Med 145: 212-220, 2005
80. Kilickap S, Barista I, Akgul E, et al: cTnT can be a useful marker for early detection of anthracycline cardiotoxicity. Ann Oncol 16: 798-804, 2005
81. Cardinale D, Colombo A, Torrisi R, et al: Trastuzumab-induced cardiotoxicity: Clinical and prognostic implications of troponin I evaluation. J Clin Oncol 28: 3910-3916, 2010
82. Morris PG, Chen C, Steingart R, et al: Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib. Clin Cancer Res 17: 3490-3499, 2011
83. Cardinale D, Sandri MT, Martinoni A, et al: Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol 13: 710-715, 2002
84. Cardinale D, Sandri MT, Colombo A, et al: Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 109: 2749-2754, 2004
85. Ederhy S, Massard C, Dufaitre G, et al: Frequency and management of troponin I elevation in patients treated with molecular targeted therapies in phase I trials. Invest New Drugs 30: 611-615, 2012
86. Schmidinger M, Zielinski CC, Vogl UM, et al: Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 26: 5204-5212, 2008
87. Auner HW, Tinchon C, Linkesch W, et al: Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann Hematol 82: 218-222, 2003
88. Okumura H, Iuchi K, Yoshida T, et al: Brain natriuretic peptide is a predictor of anthracyclineinduced cardiotoxicity. Acta Haematol 104: 158-163, 2000
89. Meinardi MT, van Veldhuisen DJ, Gietema JA, et al: Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol 19: 2746-2753, 2001
90. Nousiainen T, Vanninen E, Jantunen E, et al: Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction. J Intern Med 251: 228-234, 2002
91. Daugaard G, Lassen U, Bie P, et al: Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction. Eur J Heart Fail 7: 87-93, 2005
92. Pichon MF, Cvitkovic F, Hacene K, et al: Druginduced cardiotoxicity studied by longitudinal B-type natriuretic peptide assays and radionuclide ventriculography. In Vivo 19: 567-576, 2005
93. Knobloch K, Tepe J, Lichtinghagen R, et al: Simultaneous hemodynamic and serological cardiotoxicity monitoring during immunotherapy with trastuzumab. Int J Cardiol 125: 113-115, 2008
94. Kittiwarawut A, Vorasettakarnkij Y, Tanasanvimon S, et al: Serum NT-proBNP in the early detection of doxorubicin-induced cardiac dysfunction. Asia Pac J Clin Oncol 9: 155-161, 2013
95. Horacek JM, Pudil R, Jebavy L, et al: Assessment of anthracycline-induced cardiotoxicity with biochemical markers. Exp Oncol 29: 309-313, 2007
96. Dodos F, Halbsguth T, Erdmann E, et al: Usefulness of myocardial performance index and biochemical markers for early detection of anthracyclineinduced cardiotoxicity in adults. Clin Res Cardiol 97: 318-326, 2008
97. Perik PJ, Rikhof B, de Jong FA, et al: Results of plasma N-terminal pro B-type natriuretic peptide and cardiac troponin monitoring in GIST patients do not support the existence of imatinib-induced cardiotoxicity. Ann Oncol 19: 359-361, 2008
98. Romano S, Fratini S, Ricevuto E, et al: Serial measurements of NT-proBNP are predictive of nothigh-dose anthracycline cardiotoxicity in breast cancer patients. Br J Cancer 105: 1663-1668, 2011
99. Sandri MT, Salvatici M, Cardinale D, et al: Nterminal pro-B-type natriuretic peptide after highdose chemotherapy: A marker predictive of cardiac dysfunction? Clin Chem 51: 1405-1410, 2005
100. Onitilo AA, Engel JM, Stankowski RV, et al: High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: A pilot study. Breast Cancer Res Treat 134: 291-298, 2012
101. Stoodley PW, Richards DAB, Boyd A, et al: Altered left ventricular longitudinal diastolic function correlates with reduced systolic function immediately after anthracycline chemotherapy. Eur Heart J Cardiovasc Imaging 14: 228-234, 2013
102. Stoodley PW, Richards DAB, Boyd A, et al: Left ventricular systolic function in HER2/neu negative breast cancer patients treated with anthracycline chemotherapy: A comparative analysis of left ventricular ejection fraction and myocardial strain imaging over 12 months. Eur J Cancer 49: 3396-3403, 2013
103. Motoki H, Koyama J, Nakazawa H, et al: Torsion analysis in the early detection of anthracyclinemediated cardiomyopathy. Eur Heart J Cardiovasc Imaging 13: 95-103, 2012
104. Mantovani G, Madeddu C, Cadeddu C, et al: Persistence, up to 18 months of follow-up, of epirubicin-induced myocardial dysfunction detected early by serial tissue Doppler echocardiography: Correlation with inflammatory and oxidative stress markers. Oncologist 13: 1296-1305, 2008
105. Florescu M, Magda LS, Enescu OA, et al: Early detection of epirubicin-induced cardiotoxicity in patients with breast cancer. J Am Soc Echocardiogr 27: 83-92, 2014
106. Fallah-Rad N, Walker JR, Wassef A, et al: The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor IIpositive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol 57: 2263-2270, 2011
107. Belham M, Kruger A, Mepham S, et al: Monitoring left ventricular function in adults receiving anthracycline-containing chemotherapy. Eur J Heart Fail 9: 409-414, 2007
108. Murbraech K, Smeland KB, Holte H, et al: Heart failure and asymptomatic left ventricular systolic dysfunction in lymphoma survivors treated with autologous stem-cell transplantation: A national cross-sectional study. J Clin Oncol 33: 2683-2691, 2015
109. Ho E, Brown A, Barrett P, et al: Subclinical anthracycline-and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: A speckle tracking echocardiographic study. Heart 96: 701-707, 2010
110. Chow EJ, Baker KS, Lee SJ, et al: Influence of conventional cardiovascular risk factors and lifestyle characteristics on cardiovascular disease after hematopoietic cell transplantation. J Clin Oncol 32: 191-198, 2014
111. Maraldo MV, Ng AK: Minimizing cardiac risks with contemporary radiation therapy for Hodgkin lymphoma. J Clin Oncol 34: 208-210, 2016
112. Gagliardi G, Constine LS, Moiseenko V, et al: Radiation dose-volume effects in the heart. Int J Radiat Oncol Biol Phys 76: S77-S85, 2010 (suppl 3)
113. Von Hoff DD, Layard MW, Basa P, et al: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91: 710-717, 1979
114. Speyer JL, Green MD, Zeleniuch-Jacquotte A, et al: ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 10: 117-127, 1992
115. Swain SM, Whaley FS, Ewer MS: Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer 97: 2869-2879, 2003
116. Darby SC, Ewertz M, McGale P, et al: Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 368: 987-998, 2013
117. Maraldo MV, Giusti F, Vogelius IR, et al: Cardiovascular disease after treatment for Hodgkin's lymphoma: An analysis of nine collaborative EORTCLYSA trials. Lancet Haematol 2: e492-e502, 2015
118. van Nimwegen FA, Schaapveld M, Cutter DJ, et al: Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma. J Clin Oncol 34: 235-243, 2016
119. Armenian SH, Sun CL, Francisco L, et al: Late congestive heart failure after hematopoietic cell transplantation. J Clin Oncol 26: 5537-5543, 2008
120. Slamon D, Eiermann W, Robert N, et al: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365: 1273-1283, 2011
121. Slamon D, Eiermann W, Robert N, et al: Ten year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (ACT) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab(ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER21 early breast cancer Cancer Res 76: 2016 (abstr S5-04)
122. Bellinger AM, Arteaga CL, Force T, et al: Cardio-oncology: How new targeted cancer therapies and precision medicine can inform cardiovascular discovery. Circulation 132: 2248-2258, 2015
123. Armenian SH, Xu L, Ky B, et al: Cardiovascular disease among survivors of adult-onset cancer: A community-based retrospective cohort study. J Clin Oncol 34: 1122-1130, 2016
124. Rafiyath SM, Rasul M, Lee B, et al: Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: A meta-analysis. Exp Hematol Oncol 1: 10, 2012
125. Lopez M, Vici P, Di Lauro K, et al: Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas. J Clin Oncol 16: 86-92, 1998
126. Marty M, EspiéM, Llombart A, et al: Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy. Ann Oncol 17: 614-622, 2006
127. Venturini M, Michelotti A, Del Mastro L, et al: Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. J Clin Oncol 14: 3112-3120, 1996
128. Casper ES, Gaynor JJ, Hajdu SI, et al: A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors. Cancer 68: 1221-1229, 1991
129. Hortobagyi GN, Yap HY, Kau SW, et al: A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer. Am J Clin Oncol 12: 57-62, 1989
130. Shapira J, Gotfried M, Lishner M, et al: Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen: A prospective randomized evaluation. Cancer 65: 870-873, 1990
131. Zalupski M, Metch B, Balcerzak S, et al: Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: A Southwest Oncology Group study. J Natl Cancer Inst 83: 926-932, 1991
132. Rifkin RM, Gregory SA, Mohrbacher A, et al: Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: A phase III multicenter randomized trial. Cancer 106: 848-858, 2006
133. Northfelt DW, Dezube BJ, Thommes JA, et al: Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDSrelated Kaposi's sarcoma: Results of a randomized phase III clinical trial. J Clin Oncol 16: 2445-2451, 1998
134. Cardinale D, Colombo A, Sandri MT, et al: Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114(23): 2474-2481
135. Kalay N, Basar E, Ozdogru I, et al: Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 48: 2258-2262, 2006
136. Bosch X, Rovira M, Sitges M, et al: Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: The OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol 61: 2355-2362, 2013
137. Gulati G, Heck SL, Ree AH, et al: Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): A 2 3 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan andmetoprolol. Eur Heart J 37: 1671-1680, 2016
138. Boekhout AH, Gietema JA,Milojkovic Kerklaan B, et al: Angiotensin II-receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer: A randomized clinical trial. JAMA Oncol 2: 1030-1037, 2016
139. Pituskin E, Haykowsky M, Mackey JR, et al: Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101-Breast): A randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER21 early breast cancer using cardiac MRI. BMC Cancer 11: 318, 2011
140. Pituskin E, Mackey JR, Koshman S, et al: Prophylactic beta blockade preserves left ventricular ejection fraction in HER2-overexpressing breast cancer patients receiving trastuzumab: Primary results of the MANTICORE randomized, controlled trial. 2015 San Antonio Breast Cancer Symposium, San Antonio, TX, December 9, 2015 (abstr S1-05)
141. Bamias A, Lainakis G, Manios E, et al: Could rigorous diagnosis and management of hypertension reduce cardiac events in patients with renal cell carcinoma treated with tyrosine kinase inhibitors? J Clin Oncol 27: 2567-2569, 2009
142. Engert A, Plütschow A, Eich HT, et al: Reduced treatment intensity in patientswith early-stage Hodgkin's lymphoma. N Engl J Med 363: 640-652, 2010
143. Maraldo MV, Brodin NP, Vogelius IR, et al: Risk of developing cardiovascular disease after involved node radiotherapy versus mantle field for Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 83: 1232-1237, 2012
144. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology. Breast Cancer Version 1. Fort Washington, PA, National Comprehensive Cancer Network, 2016
145. Barac A: Yet another player in the cardiooncology conundrum? Deciphering the role of FLT3. J Am Coll Cardiol 63: 1020-1021, 2014
146. Christian JB, Finkle JK, Ky B, et al: Cardiac imaging approaches to evaluate drug-induced myocardial dysfunction. Am Heart J 164: 846-855, 2012
147. Nagueh SF, Smiseth OA, Appleton CP, et al: Recommendations for the evaluation of left ventricular diastolic function by echocardiography: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 29: 277-314, 2016
148. Lang RM, Bierig M, Devereux RB, et al: Recommendations for chamber quantification: A report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18: 1440-1463, 2005
149. Nousiainen T, Jantunen E, Vanninen E, et al: Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma. Eur J Haematol 62: 135-141, 1999
150. Negishi K, Negishi T, Hare JL, et al: Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echocardiogr 26: 493-498, 2013
151. Voigt JU, Pedrizzetti G, Lysyansky P, et al: Definitions for a common standard for 2D speckle tracking echocardiography: Consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. J Am Soc Echocardiogr 28: 183-193, 2015
152. Plana JC, Galderisi M, Barac A, et al: Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: A report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 27: 911-939, 2014
153. Allen LA, Yood MU, Wagner EH, et al: Performance of claims-based algorithms for identifying heart failure and cardiomyopathy among patients diagnosed with breast cancer. Med Care 52: e30-e38, 2014
154. The SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327: 685-691, 1992
155. Cardinale D, Colombo A, Lamantia G, et al: Anthracycline-induced cardiomyopathy: Clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 55: 213-220, 2010
156. Thavendiranathan P, Grant AD, Negishi T, et al: Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: Application to patients undergoing cancer chemotherapy. J Am Coll Cardiol 61: 77-84, 2013
157. Kotwinski P, Smith G, Sanders J, et al: The breast cancer, early disease: Toxicity from therapy with epirubicin regimens-cardiac assessment and risk evaluation (BETTER-CARE) study: CMR with early gadolinium relative enhancement, but not highsensitivity troponin T, predicts the risk of chronic anthracycline cardiotoxicity. J Cardiovasc Magn Reson 15: O94, 2013 (suppl 1)
158. Shelburne N, Adhikari B, Brell J, et al: Cancer treatment-related cardiotoxicity: Current state of knowledge and future research priorities. J Natl Cancer Inst 106: dju232, 2014
159. Mead H, Cartwright-Smith L, Jones K, et al: Racial and Ethnic Disparities in U.S. Health Care: A Chartbook. New York, NY, Commonwealth Fund, 2008
160. Tammemagi CM, Nerenz D, Neslund-Dudas C, et al: Comorbidity and survival disparities among black and white patients with breast cancer. JAMA 294: 1765-1772, 2005
161. DeSantis C, Ma J, Bryan L, et al: Breast cancer statistics, 2013. CA Cancer J Clin 64: 52-62, 2014